Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Increase in Short Interest

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 14,745 shares, an increase of 233.4% from the May 14th total of 4,423 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average trading volume of 6,576 shares, the days-to-cover ratio is currently 2.2 days.

Bavarian Nordic Stock Performance

Shares of OTCMKTS BVNRY traded up $0.05 during midday trading on Friday, hitting $9.43. 4,000 shares of the stock traded hands, compared to its average volume of 3,400. The company has a market cap of $2.24 billion, a PE ratio of 12.40 and a beta of 1.19. Bavarian Nordic has a one year low of $8.66 and a one year high of $13.00. The business has a 50 day moving average price of $9.90 and a two-hundred day moving average price of $9.93.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 EPS for the quarter. The firm had revenue of $165.70 million during the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.